Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy.
Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R.
Haghikia A, et al. Among authors: gruter t.
Lancet Neurol. 2017 Feb;16(2):104-106. doi: 10.1016/S1474-4422(16)30382-9.
Lancet Neurol. 2017.
PMID: 28102146
No abstract available.